NuProbe specializes in advanced genomic technologies aimed at enhancing the detection and quantification of low-abundance DNA variants, particularly in the context of oncology research. One of their key innovations is the Blocker Displacement Amplification (BDA) technology, which allows for the selective amplification of rare alleles down to a variant allele frequency of 0.01%. This technology is particularly valuable for identifying low-level variants that are often missed by conventional methods. Additionally, NuProbe employs Quantitative Amplicon Sequencing (QASeq), a next-generation sequencing (NGS) method that utilizes unique molecular identifiers and highly multiplexed PCR primer designs to achieve high sensitivity in detecting mutations and copy number variations.

NuProbe's products are designed to support both clinical and research laboratories in the detection of difficult DNA biomarkers, including copy number variations (CNVs) and gene fusions. Their assays are applicable to various sample types, including cell-free DNA and formalin-fixed paraffin-embedded (FFPE) tissues, making them versatile tools for cancer research and biomarker detection. The company also offers custom assay development and biopharma services, leveraging their proprietary technologies to provide high-sensitivity solutions for solid tumors and liquid biopsies, thereby accelerating precision oncology efforts worldwide.

United States

The NuProbe team has pioneered the development of a unique and novel PCR-based enrichment method called Blocker Displacement Amplification (BDA). The BDA technology enables the selective amplification of low abundant sequence variants (SNV and indels) in a background of wildtype DNA.

NuProbe

Company Details